Our mission is to develop vectorized antibodies for neurodegenerative diseases, enabling longer, better lives
Our programs
We have a strong pipeline of potentially disease-modifying vectorized antibody treatments for neurodegenerative diseases including ALS, Huntington’s, and Parkinson’s disease.
The platform
Based on extensive internal knowhow, a unique platform has been developed that combines state-of-the-art intracellular antibodies, AAV capsids, and manufacturing.
What’s new
VectorY appoints Khurem Farooq to Board of Directors
VectorY Raises €129 Million ($138 Million) Series A Financing to Advance Vectorized Antibody Programs in Neurodegenerative Diseases
VectorY to Present at Bio€quity Europe
VectorY to Participate in Key Sector Conferences in April 2023
VectorY Appoints Mike Wyzga as CFO and adds Jean Franchi to its Board of Directors
Work at VectorY
We are growing fast and therefore we are always looking for enthusiastic and dedicated professionals to join our team. Learn more about working at VectorY and search job openings.